A Randomized, Placebo-Controlled, Subject- and Investigator-Blind, Single and Multiple Dose, Safety, Tolerability, and Pharmacokinetics Study of LY3463251 in Healthy and Overweight Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2019
At a glance
- Drugs LY 3463251 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 20 Jan 2019 Planned End Date changed from 22 Aug 2019 to 21 Sep 2020.
- 20 Jan 2019 Planned primary completion date changed from 22 Aug 2019 to 21 Sep 2020.
- 18 Dec 2018 Status changed from not yet recruiting to recruiting.